Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma

Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma

(2019) Andrew B. Lassman et al.   CLINICAL CANCER RESEARCH

Effect of therapeutic pressure on stability of EGFR amplification in glioblastoma.

(2018) Manmeet Singh Ahluwalia et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).

(2018) Martin J. Van Den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

LTBK-04 FIRST RESULTS OF THE RANDOMIZED PHASE II STUDY ON DEPATUX –M ALONE, DEPATUX-M IN COMBINATION WITH TEMOZOLOMIDE AND EITHER TEMOZOLOMIDE OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA: FIRST REPORT FROM INTELLANCE 2/EORTC TRIAL 1410

(2017) Martin van den Bent et al.   NEURO-ONCOLOGY

146P Tolerability and pharmacokinetics (PK) of ABT-414 in Japanese patients (pts) with recurrent malignant glioma

(2016) Y. Narita et al.   ANNALS OF ONCOLOGY

ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope

(2016) A. C. Phillips et al.   MOLECULAR CANCER THERAPEUTICS

Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas

(2015) Martin J. van den Bent et al.   NEURO-ONCOLOGY

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry

(2015) Pei Yang et al.   Oncotarget

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered

(2013) Hui K. Gan et al.   FEBS Journal

Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab

(2012) SHASHA LV et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group

(2012) Wei Yan et al.   NEURO-ONCOLOGY

Correlation of IDH1 Mutation with Clinicopathologic Factors and Prognosis in Primary Glioblastoma: A Report of 118 Patients from China

(2012) Wei Yan et al.   PLoS One

Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement

(2011) Hye Ryun Kim et al.   CANCER

IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas

(2011) Song-Τao Qi   ONCOLOGY REPORTS

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Validation and Simplification of the Radiation Therapy Oncology Group Recursive Partitioning Analysis Classification for Glioblastoma

(2010) Jing Li et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of a Real-time RT-PCR Assay for Detecting EGFRvIII in Glioblastoma Samples

(2008) K. Yoshimoto et al.   CLINICAL CANCER RESEARCH